{"id":"hcp1202","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously activating GLP-1 and GIP receptors, HCP1202 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater improvements in blood glucose control and body weight reduction compared to single GLP-1 agonists, with a favorable safety profile in early clinical development.","oneSentence":"HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:49.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02941679","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HCP1202 Capsule"],"phase":"phase_3","status":"active","brandName":"HCP1202","genericName":"HCP1202","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}